Myriad Genetics Stock

Myriad Genetics FCF Yield

The Free Cash Flow Yield of Myriad Genetics (MYGN) as of Aug 6, 2026 is -5.76 %. In the previous year, Free Cash Flow Yield was -8.65 % — a change of -33.33% (higher).

FCF Yield

-5.76 %

YoY

-33.33%

Last updated:

Free Cash Flow Yield of Myriad Genetics is 2026 -5.76 % . Free Cash Flow Yield of Myriad Genetics was 2025 -8.65 % . It decreases by -33.33% higher compared to the previous year.
Access this data via the Eulerpool API

Myriad Genetics Stock analysis

What does Myriad Genetics do? Myriad Genetics Inc. is a biotechnology company specializing in the research of cancer and genetic analysis technologies. The company was founded in 1991 by Mark Skolnick and has since become a global leader in personalized medicine and diagnostics. It is headquartered in Salt Lake City, Utah, USA, and employs over 2,400 employees worldwide. Myriad Genetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myriad Genetics stock

Free Cash Flow Yield of Myriad Genetics is -5.76 % in 2026.

Free Cash Flow Yield of Myriad Genetics changed from -8.65 % to -5.76 %, representing a -33.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Myriad Genetics since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Myriad Genetics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Myriad Genetics

All Key Metrics — Myriad Genetics